FDA approves Ryoncil for steroid-refractory acute graft-versus-host after allo-HSCT
The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...
Hosted on MSN8h
FDA Approves Groundbreaking Cell Therapy for Life-Threatening Pediatric Disease
A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...
FiercePharma8d
After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.
Hosted on MSN8d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...
clinicaladvisor.com1d
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Cure Today9d
Ryoncil Receives FDA Approval for Children With GVHD
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Benzinga.com8d
What's Going On With Mesoblast Shares Thursday?
Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...
Mesoblast’s Ryoncil: A Breakthrough in Pediatric Therapy
Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
Mesoblast RYONCIL becomes first FDA-approved mesenchymal stromal cell therapy
Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in ...
Mesoblast awarded FDA approval for Ryoncil
Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...